Dicot Pharma Dicot Pharma
På svenska

We develop the next generation potency drug.

To enhance quality of life for men and couples worldwide.

Over 500 million men worldwide suffer from erectile dysfunction and premature ejaculation. Dicot Pharma is developing an entirely new potency drug aimed at creating a treatment with longer duration, fewer side effects, and effectiveness for a significantly broader group compared to existing market alternatives. Clinical studies are currently underway, with Phase 2a completed and its results expected in autumn 2025.

Press Releases

Dicot Pharma’s World in Numbers

Approx.
billion SEK/year
The global sales of erectile dysfunction treatments.
Approx.
percent
The proportion of men with erectile dysfunction who discontinue treatment with current medications.
At least
days
LIB-01's duration from exploratory measurements in the Phase 1 study.
percent
The number of shareholders has doubled in one year.

Dicot Pharma highlighted in Oppenheimer’s report

The global investment bank Oppenheimer has published an equity research report where Dicot Pharma and LIB-01 for the treatment of erectile dysfunction are singled out as being of particular interest. The report is part of Oppenheimer’s focus on longevity as the next major trend for biotech investors and highlights a clear link between erectile dysfunction and healthy aging.

Financial calendar and events

Dutch TV highlights Swedish innovation

RTL’s channels reach 98% of the Dutch population every week. In one of their segments on innovative Swedish companies, Elin Trampe is interviewed about Dicot Pharma’s vision and the clinical work partly conducted in the Netherlands.